PTPeter Takacs

Peter Takacs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Takacs has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Randomized controlled trial of adjunctive zinc-containing vaginal hydrogel following fluconazole therapy for vulvovaginal candidiasis

    by Dávid Rátonyi, Barbara Kozma, Bence Kozma, Attila G. Sipos, Peter Takacs

    Background: Recurrent and persistent vulvovaginal candidiasis remain clinically challenging, and supportive strategies that improve post-treatment microbiological stability are needed. Zinc-containing vaginal hydrogel may influence local host–pathogen interactions, but clinical data on its adjunctive use after fluconazole are limited. Methods: This single-center, two-arm, parallel-group randomized clinical trial compared standard oral fluconazole therapy alone with fluconazole followed by adjunctive zinc-containing vaginal hydrogel. Women with symptomatic acute vulvovaginal candidiasis were assessed at baseline, week 4, week 8, and week 12. The primary outcome was clinical cure, defined as Candida Severity Score < 3. Secondary outcomes included symptom severity, Vaginal Health Index, mycological cure, and interim antifungal treatment. A post-clearance recurrence cohort included participants with both clinical and mycological clearance at week 4. Results: Fifty-four women were included in the modified intention-to-treat cohort: 22 controls and 32 hydrogel-treated participants. Clinical cure did not differ significantly between groups at week 4, week 8, or week 12. Longitudinal models showed no significant group-by-time interaction for clinical cure, Candida Severity Score, Vaginal Health Index, VSQ-21, or interim antifungal treatment. At week 12, mycological cure was numerically more frequent in the hydrogel group than in controls, without reaching statistical significance (65.6% vs. 40.9%; OR = 2.76, 95% CI 0.90–8.45; p = 0.097). In the exploratory post-clearance recurrence cohort, week-12 culture negativity was observed in 14/14 hydrogel-treated participants and 11/17 controls (100.0% vs. 64.7%; p = 0.021), corresponding to microbiological culture recurrence rates of 0.0% and 35.3%, respectively. Conclusion: Adjunctive zinc-containing vaginal hydrogel following oral fluconazole was not associated with a significant improvement in acute clinical cure in the overall study population. The observed maintenance of fungal culture negativity among women with documented early clinical and mycological clearance should be interpreted as an exploratory microbiological signal rather than definitive evidence of clinical recurrence prevention. Larger placebo-controlled trials specifically designed and powered for recurrent vulvovaginal candidiasis and culture-confirmed recurrence are needed. The study protocol was approved by the Hungarian National Institutional Review Medical Research Council (approval No. 3282-7/2023/EUIG). All participants provided written informed consent before any study-related procedure. The trial was registered at ClinicalTrials.gov (NCT05895162; registration date: 15 May 2023).

  • Development and bioavailability testing of an estetrol and estetrol-zinc-containing vaginal hydrogel: a novel hydroxyethyl cellulose and hydroxypropyl-β-cyclodextrin-based formulation

    by Peter MD Takacs, Dávid Rátonyi, Barbara Kozma, Alexandra Kunkli, Ferenc Pharm.D Fenyvesi, Kindra Larson, Attila G. Sipos, Bence Kozma

    Objective: Genitourinary syndrome of menopause (GSM) significantly impacts postmenopausal women, yet conventional treatments, such as vaginal estrogen creams, have limitations related to adherence and efficacy. This study aims to develop and evaluate a novel hydroxyethyl cellulose (HEC)-based bioadhesive vaginal hydrogel containing estetrol (E4) and estetrol-zinc, with hydroxypropyl-β-cyclodextrin (HPβCD) as an excipient, to enhance drug retention, bioavailability, and patient compliance. Methods: The hydrogel formulations (E4/200 and E4/200/CN) were prepared and characterized for solubility, stability, and drug release. In vitro biocompatibility was assessed using HaCaT keratinocyte and reconstituted human vaginal epithelium models through methyl tetrazolinium (MTT) and lactate dehydrogenase (LDH) cytotoxicity assays. Permeability was evaluated using a reconstructed vaginal epithelial model. Statistical significance was determined using appropriate tests ( t test, ANOVA). Results: The phase-solubility study demonstrated a stable 1:1 complexation between E4 and HPβCD, improving drug solubility. The hydrogels exhibited excellent biocompatibility, without cytotoxic effects on vaginal epithelial cells ( P <0.0001). Permeability testing confirmed E4 retention within vaginal tissues, reducing systemic exposure. The hydrogel formulations ensured sustained and controlled drug release. Conclusions: The estetrol-containing HEC-based and HPβCD-based vaginal hydrogel is nontoxic, and the estetrol is readily bioavailable. The formulation enhances estetrol bioavailability while ensuring localized, controlled release and optimizing therapeutic efficacy. Future clinical trials are required to confirm in vivo effectiveness and long-term safety.